Exelixis Inc (EXEL)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $16.37B
Last updated: Nov 17, 2026 at 4:33 PM ET
Exelixis Inc (EXEL) Statistics
Exelixis (EXEL) has a market cap of $16.37B and an enterprise value of $16.09B. Its share count is down 7.99% from a year earlier. It kept 35.33% of revenue as net income over the last 12 months.
Total Valuation
Enterprise value is 1.72% below the market cap, as cash exceeds debt.
| Market Cap | $16.37B |
|---|---|
| Enterprise Value | $16.09B |
| Latest price (Nov 17, 2026) | $68.50 |
Key Dates
The next earnings report is expected on Feb 8, 2027, covering the quarter ending Dec 31, 2026.
| Next Earnings Date | Feb 8, 2027 (expected) |
|---|---|
| Last Earnings Date | Oct 29, 2026 |
| Fiscal Year End | December |
Valuation Ratios
Sales and book value multiples are 7.1x and 9.3x. Its year-end P/E ranged from 13.8x to 59.6x from 2017 to 2025.
| P/E Ratio | 19.7x |
|---|---|
| Forward P/E | 19.6x |
| P/S Ratio | 7.1x |
| Forward P/S | 6.4x |
| P/B Ratio | 9.3x |
| P/TBV Ratio | 9.7x |
| P/FCF Ratio | 14.7x |
| P/OCF Ratio | 13.8x |
| PEG Ratio | 2.4 |
Enterprise Valuation
Counting debt and cash, the company is valued at 16.9x EBITDA and 14.4x free cash flow.
| EV / Earnings | 18.7x |
|---|---|
| EV / Sales | 6.6x |
| EV / EBITDA | 16.9x |
| EV / FCF | 14.4x |
Price Statistics
The stock is up 64.47% over 52 weeks and trades 9.32% above its 50-day average.
| Beta (1Y) | 0.63 |
|---|---|
| 52-Week Change | +64.47% |
| 1-Month Change | +9.29% |
| 3-Month Change | +25.94% |
| 6-Month Change | +40.74% |
| 5-Year Change | +222.59% |
| 10-Year Change | +555.24% |
| Total Return (1Y) | +64.47% |
| Total Return (3Y CAGR) | +47.99% |
| Total Return (5Y CAGR) | +31.42% |
| Return vs SPY (1Y) | +49.05% |
| Max Drawdown (1Y) | -12.59% |
| Max Drawdown (3Y) | -25.34% |
| Sharpe Ratio (1Y) | 1.41 |
| Correlation with SPY (1Y) | 0.26 |
| 50-Day Average | $62.66 |
| 200-Day Average | $52.50 |
| 52-Week Range | $39.71 to $73.69 |
| RSI (14 Days) | 55.8 |
| Average Volume (20 Days) | 2.90M |
The 5 and 10 year changes compare month-end closes, adjusted for splits, through Oct 2026.
Financial Position
Current assets cover 3.46x current liabilities, and total debt is 0.00x shareholder equity.
| Current Ratio | 3.46x |
|---|---|
| Quick Ratio | 3.38x |
| Debt / Equity | 0.00x |
Returns and Efficiency
Return on equity is 46.68% over the last 12 months, against a 5-year average of 17.28%.
| Return on Equity (ROE) | 46.68% |
|---|---|
| Return on Assets (ROA) | 34.50% |
| ROE (5Y Average) | 17.28% |
| ROA (5Y Average) | 13.40% |
| ROIC (5Y Average) | 33.55% |
| Asset Turnover | 0.94x |
| Inventory Turnover | 3.10x |
| Receivables Turnover | 7.48x |
| Cash Conversion Cycle | 32 days |
Taxes
Income tax took 16.89% of pretax income over the last 12 months.
| Income Tax (TTM) | $174.84M |
|---|---|
| Effective Tax Rate | 16.89% |
Scores
EXEL has an Altman Z-Score of 18.39, in the safe zone above 2.99, and a Piotroski F-Score of 6 of 9, in the average band of 3 to 7.
Altman Z-ScoreDistress below 1.81Safe above 2.99
Piotroski F-ScoreWeak at 2 or lessStrong at 8 or more
| Altman Z-Score | 18.39 |
|---|---|
| Altman Z Zone | Safe |
| Piotroski F-Score | 6 of 9 |
| Piotroski Strength | Average |
Income Statement
Revenue of $2.44B over the last 12 months is up 9.23% from the 12 months before.
| Revenue | $2.44B |
|---|---|
| Revenue Growth (YoY) | +9.23% |
| Gross Profit | $2.35B |
| Operating Income | $971.51M |
| Pretax Income | $1.04B |
| Net Income | $860.62M |
| Reported EPS (TTM) | $3.48 |
Trailing 12 months through Jun 30, 2026.
Balance Sheet
Shareholder equity funds 73.90% of the $2.49B in total assets.
| Cash and Equivalents | $281.45M |
|---|---|
| Total Debt | $0 |
| Net Cash | $281.45M |
| Net Cash Per Share | $1.12 |
| Working Capital | $888.89M |
| Shareholder Equity | $1.84B |
| Book Value Per Share | $7.35 |
| Tangible Book Value | $1.78B |
| Tangible Book Per Share | $7.10 |
| Total Assets | $2.49B |
| Total Liabilities | $650.47M |
Balance sheet as of Jun 30, 2026.
Cash Flow
After $10.96M of capital spending, operating cash flow left $1.17B of free cash flow.
| Operating Cash Flow | $1.18B |
|---|---|
| Capital Expenditures | $10.96M |
| Free Cash Flow | $1.17B |
| FCF Per Share | $4.73 |
| Depreciation and Amortization | $28.30M |
| Share Repurchases | $1.11B |
Trailing 12 months through Jun 30, 2026.
Margins
The operating margin is 39.88%, against a 5-year average of 21.46%.
| Gross Margin | 96.48% |
|---|---|
| Operating Margin | 39.88% |
| Pretax Margin | 42.51% |
| Net Margin | 35.33% |
| FCF Margin | 48.13% |
| Gross Margin (5Y Average) | 96.33% |
| Operating Margin (5Y Average) | 21.46% |
| Net Margin (5Y Average) | 19.31% |
Growth
Revenue grew 12.93% a year over 3 years, and EPS 55.61% a year.
| Revenue Growth (3Y CAGR) | +12.93% |
|---|---|
| Revenue Growth (5Y CAGR) | +18.63% |
| EPS Growth (3Y CAGR) | +55.61% |
| EPS Growth (5Y CAGR) | +37.88% |
| FCF Growth (3Y CAGR) | +37.77% |
| FCF Growth (5Y CAGR) | +37.43% |
| Operating Income Growth (3Y CAGR) | +62.98% |
| Book Value Per Share Growth (2Y CAGR) | +2.97% |
| Tangible Book Per Share Growth (2Y CAGR) | +2.90% |
Dividends and Yields
EXEL does not pay a dividend. Its free cash flow yield is 6.82%.
| Earnings Yield | 5.08% |
|---|---|
| FCF Yield | 6.82% |
| Buyback Yield | 6.29% |
| Shareholder Yield | 6.29% |
Peer Position
Against 3 similar companies, EXEL has the 3rd highest P/E.
P/E RatioPeer median 26.4x
P/S RatioPeer median 15.5x
Revenue Growth (Trailing 4 Quarters, YoY)Peer median +86.87%
| P/E Ratio | 19.7x vs 26.4x median |
|---|---|
| P/S Ratio | 7.1x vs 15.5x median |
| Revenue Growth (Trailing 4 Quarters, YoY) | +9.23% vs +86.87% median |
Analyst Forecast
Consensus estimates put revenue growth at 11.34% and EPS growth at 17.61% a year over the next 2 fiscal years.
| Revenue Growth Forecast (2Y CAGR) | +11.34% |
|---|---|
| EPS Growth Forecast (2Y CAGR) | +17.61% |
Price Target
Analyst price targets are part of paid GNG plans. See plans
GNG Valuation
| GNG view | Fairly valued |
|---|
GNG fair value is part of GNG Pro. See plans
Frequently Asked Questions About EXEL
What is EXEL's market cap?
Exelixis has a market cap of $16.37B. Its enterprise value, which adds debt and subtracts cash, is $16.09B.
What is EXEL's P/E ratio?
Exelixis has a trailing P/E ratio of 19.7x and a forward P/E of 19.6x.
How many shares of EXEL are outstanding?
Exelixis has 250.81M shares outstanding. The count is down 7.99% from a year earlier.
Does EXEL pay a dividend?
No. Exelixis does not pay a dividend.
How much debt does EXEL have?
Exelixis has $0 of total debt and $281.45M of cash and equivalents, a net cash position of $281.45M.
EXEL pages: Overview, Charting, Earnings, Forecast, Financials, Statistics, Valuation, Competitors